Vaccine Could Stop Nicotine from Reaching the Brain

Vaccine Could Stop Nicotine from Reaching the Brain

May 1, 2012

The new antismoking technique uses nanoparticles to trigger an immune response.

By Conor Myhrvold

Seahorse Announces the XF Glycolysis Stress Test Kit

Seahorse Announces the XF Glycolysis Stress Test Kit

April 25, 2012

BILLERICA, Mass., April 25, 2012 -- /PRNewswire/ -- Seahorse Bioscience, the leader in cellular bioenergetic measurements, announced the launch of its newest stress test kit at the American Association of Cancer Research (AACR) Annual Meeting 2012. The XF Glycolysis Stress Test Kit is the first Standard for measuring glycolytic capacity in cells.

Dr. Noubar Afeyan, Flagship's Managing Partner and CEO, speaking on Investor Panel at BIO World Congress on Industrial Biotechnology & Bioprocessing

Dr. Noubar Afeyan, Flagship's Managing Partner and CEO, speaking on Investor Panel at BIO World Congress on Industrial Biotechnology & Bioprocessing

April 30, 2012

 Click here to see announcement.

Michigan Growth Capital Symposium Unveils Flagship Ventures' Noubar Afeyan as Keynote Speaker

Michigan Growth Capital Symposium Unveils Flagship Ventures' Noubar Afeyan as Keynote Speaker

April 24, 2012

Society for Biological Engineering Announces Inaugural Winners of Wang Award

Society for Biological Engineering Announces Inaugural Winners of Wang Award

April 17, 2012

NEW YORK – The Society for Biological Engineering (SBE) of the American Institute of Chemical Engineers (AIChE) has announced the inaugural winners of the D. I. C. Wang Award for Excellence in Biochemical Engineering. The inaugural recipients of the award, established in appreciation of Professor Daniel I.C. Wang of the Massachusetts Institute of Technology (MIT), are Noubar Afeyan of Flagship Ventures and James Swartz of Stanford University.

Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business

Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business

April 12, 2012
DUBLIN, April 12, 2012 /PRNewswire/ --

Tangent Medical Submits FDA 510(k) for NovaCath™ Secure IV Catheter System

Tangent Medical Submits FDA 510(k) for NovaCath™ Secure IV Catheter System

April 10, 2012
Innovative Closed Catheter System To Offer Advanced Catheter Stabilization On Every Single Start
BIND Therapeutics, Inc.

First Targeted Nanomedicine to Enter Human Clinical Studies is a Paradigm Shift in Anti-tumor Efficacy and Safety in Cancer Patients

First Targeted Nanomedicine to Enter Human Clinical Studies is a Paradigm Shift in Anti-tumor Efficacy and Safety in Cancer Patients

April 4, 2012

BOSTON, MA—A team of scientists, engineers and physicians from Brigham and Women’s Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell Medical College have found promising effects of a first-in-class targeted cancer drug called BIND-014 in treating solid tumors.

BIND Therapeutics, Inc.

Novel Prostate Nanomedicine Delivers High Drug Concentration Directlyand Safely to Tumors in Phase I Trials

Novel Prostate Nanomedicine Delivers High Drug Concentration Directlyand Safely to Tumors in Phase I Trials

April 4, 2012

Highly-Targeted Nanoparticles Act as “Trojan Horse” to Deliver Powerful Chemotherapy Agent Without Affecting Healthy Cells

Acceleron Pharma, Inc.

Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma

Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma

April 3, 2012

-- Enhanced Anti-Tumor Activity Achieved via Combination of Two Distinct Anti-Angiogenic Drugs presented at the AACR Annual Meeting 2012 --